# CANOPY FOR LIFE SCIENCES ## Deliver on the promise of treatment **Published at ASCO:** Up to 45% potential increase in patients staying on therapy. [READ](https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.1528) ## SYMPTOM MONITORING ### In cancer, silence can be the most dangerous symptom Unchecked symptoms lead to treatment disruptions. With Canopy, patients can report issues between visits so care teams act earlier and keep treatment on track. #### Targeted Treatment Check-Ins Timed, tailored, multilingual outreach captures symptoms and adherence – directly from patients. #### Risk Stratification & Escalation AI surfaces feedback to care teams and triggers appropriate outreach, helping patients get what they need – sooner. ## ENHANCED WORKFLOWS ### Novel therapies require a novel approach Modern treatments bring new complexities: stringent protocols, rigorous monitoring and other challenges to adoption. With Canopy, sponsors can provide adaptive, AI-enabled programs that help clinics deliver advanced therapies confidently. #### Therapy Orchestration Modules Native and sponsored therapy-specific workflows standardize onboarding, facilitate administration and streamline monitoring. #### Care Routing Automation Intelligent symptom-specific triggers prioritize clinical actions, triaging follow up, and when necessary, enabling patient transfer to an appropriate care facility. ## Patient Education ### Cancer is already overwhelming, patient education shouldn't be. #### Just-in-time, symptom-specific guidance Deliver targeted, symptom-specific information for patients at the moment it’s needed, reducing confusion, mis-steps and empowering effective self-care. #### Dynamic education modules AI-driven education delivers personalized, cross-journey support — helping each patient understand their therapy plan, anticipate what’s next, and stay adherent throughout treatment. ## Partner with Canopy Life Science partners collaborate with Canopy’s oncology network to help patients navigate symptoms, stay adherent, and realize the full benefit of therapy. [Learn more](https://get.canopycare.us/l/1089072/2024-12-23/3dfnp4) OUR RESEARCH Publications American Society of Hematology Annual Meeting 2025 Oral Presentation [Remote therapeutic monitoring reduces hospitalization due to infection in patients being treated for hematological malignancy.](https://ashpublications.org/blood/article/146/Supplement%201/131/554994/Remote-therapeutic-monitoring-reduces) Essell, J., Ascha, M., Schaefer, E., Calkins, G., Kwiatkowsky, L., Kolodziej, M., & Derman, B. ASCO Quality Care Symposium 2025 [Application of the remote therapeutic monitoring (RTM) platform to optimize adherence and manage toxicity of oral anti-cancer medications.](https://ascopubs.org/doi/10.1200/OP.2025.21.10_suppl.594) Sharma S, Doshi G, Hughes L, Kolodziej MA, Kwiatkowsky L, Calkins G, Ascha MS. Journal of Clinical Pathways 2025 [Remote therapeutic monitoring to support adoption of bispecific antibody therapy in community practices.](https://www.hmpgloballearningnetwork.com/site/jcp/casereview/remote-therapeutic-monitoring-support-adoption-bispecific-antibody-therapy) Essell JH, Derman BA, Brooks B, Doshi GK, Kolodziej MA, Kwiatkowsky L, Calkins G, Ascha MS. American Society of Clinical Oncology Annual Meeting 2025 [Electronic patient reported outcomes in breast cancer patients receiving adjuvant chemotherapy with doxorubicin/cyclophosphamide combined with paclitaxel compared to patients receiving docetaxel/cyclophosphamide.](https://www.asco.org/abstracts-presentations/223960) Kolodziej MA, Ascha M, Blau S, Schaefer ES, Telivala B, Calkins G, Neiman J, Kwiatkowsky L, Essell JH, Derman B, Patt D. American Society of Clinical Oncology Annual Meeting 2025 [Electronic patient-reported outcomes (ePRO) in patients with advanced melanoma receiving immune checkpoint inhibitors: Insights from the Canopy ePRO system.](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.11126) Derman B, Ascha M, Essell JH, Kwiatkowsky L, Calkins G, Neiman J, Kolodziej MA.